Van Naarden Jacob
Known title: SVP, CEO LoxoONC, Pres LlyONCCIK: 0001661254
Van Naarden Jacob's purchase track record
Van Naarden Jacob has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/13/2025 | LLY | $647K | +54.4% | +54.3% | +7.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LLY | ▲ Buy | Grant | 4,866 | $5.1M | 2/9/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 4,108 | $0 | 2/1/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,909 | $2.0M | 2/1/2026 | View on chart |
| LLY | ▲ Buy | Open Market | 1,000 | $647K | 8/13/2025 | View on chart |
| LLY | ▲ Buy | Grant | 6,104 | $5.3M | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,023 | $0 | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,410 | $1.1M | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Gift | 4,302 | $0 | 10/31/2024 | View on chart |
| LLY | ▲ Buy | Grant | 2,369 | $1.7M | 2/12/2024 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,685 | $1.1M | 2/1/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,618 | $0 | 2/1/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 2,785 | $0 | 2/16/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,314 | $440K | 2/16/2023 | View on chart |
| LLY | ▲ Buy | Grant | 2,407 | $831K | 2/10/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 5,461 | $0 | 2/16/2022 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 2,186 | $533K | 2/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.